RecruitingPhase 3NCT07037459
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
Sponsor
Amgen
Enrollment
5,056 participants
Start Date
Jun 25, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria10
- Age ≥ 18 years at the time of informed consent.
- BMI ≥ 30.0 kg/m\^2 at the time of randomization.
- HF diagnosed for at least 30 days with New York Heart Association (NYHA) Class II-IV at the time of informed consent.
- Managed with HF standard of care therapies.
- Left ventricular ejection fraction (LVEF) of \> 40% within 12 months from the beginning of screening.
- Elevated NT-proBNP.
- Participants must have at least one of the following:
- Structural heart disease within 12 months prior to screening OR
- Documented hospitalization with a primary diagnosis of decompensated HF which required IV loop diuretic treatment \> 30 days and \< 12 months prior to randomization OR
- Evidence of elevated filling pressures within 12 months before randomization.
Exclusion Criteria23
- History of any of the following within 60 days prior to or during screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke.
- HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy/dysplasia, uncorrected primary valvular heart disease, clinically significant congenital heart disease.
- Any lifetime history of LVEF ≤ 40%.
- Hospitalized with acute decompensated HF at the time of or during the screening period.
- Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes.
- For participants with a prior diagnosis of T2DM (including those diagnosed during screening):
- HbA1c \> 10.0% (86 mmol/mol) at screening
- Uncontrolled diabetes requiring immediate therapy
- History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization
- One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness
- History or presence of either proliferative diabetic retinopathy, or diabetic maculopathy, or severe non-proliferative diabetic retinopathy; or currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
- SBP ≥ 180 mmHg during the screening period, or on three or more blood pressure-lowering drugs with a SBP \> 160 mmHg during the screening period.
- History of chronic pancreatitis or acute pancreatitis in the 180 days before screening or during the screening period.
- Any personal lifetime history of, or family history(first-degree relative\[s\]) of medullary thyroid carcinoma or MEN-2.
- eGFR \< 20 mL/min/1.73 m\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening.
- Calcitonin ≥ 50 ng/L (pg/mL) at screening.
- Acute or chronic hepatitis.
- Any of the following psychiatric history:
- History of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior to screening or during the screening period
- Lifetime history of suicide attempt
- History of non-suicidal self-injury within 5 years prior to screening or during the screening period.
- History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the trial.
- Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days prior to or during the screening period or planned use during the conduct of the trial.
Interventions
DRUGMaridebart cafraglutide
Maridebart cafraglutide will be administered SC.
DRUGPlacebo
Placebo will be administered SC.
Locations(564)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07037459
Related Trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT0724708425 locations
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
NCT070107571 location
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT074817471 location
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity
NCT071375851 location